Recent

% | $
Quotes you view appear here for quick access.

InVivo Therapeutics Holdings Corp. Message Board

  • yzzycz yzzycz Jan 28, 2013 8:37 PM Flag

    InVivo CEO hopes for FDA response by early 2012

    September 8, 2011 by MassDevice staffInVivo Therapeutics CEO Frank Reynolds hopes the FDA will give the green light by early next year for a human trial of the company's biodegradable scaffold for treating traumatic spinal cord injury.

    InVivo Therapeutics (OTC:NVIV) hopes to hear back from the FDA within four weeks about its application to run the first human trials of its biodegradable scaffold for treating traumatic spinal cord injuries, according to CEO Frank Reynolds.

    News Well, Clinical Trials, Regenerative Medicine, Spinal, Wall Street Beat

 
NVIV
12.13+0.14(+1.17%)May 1 4:00 PMEDT